Charles Schwab
HCAT icon

Charles Schwab’s Health Catalyst HCAT Stock Holding History

Charles Schwab’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
615,504
+8,646
+1% +$12.5K ﹤0.01% 2945
2026
Q1 		$771K Buy
606,858
+59,891
+11% +$113K ﹤0.01% 2975
2025
Q4 		$1.31M Sell
546,967
-75,721
-12% -$207K ﹤0.01% 2841
2025
Q3 		$1.77M Buy
622,688
+24,058
+4% +$82.4K ﹤0.01% 2781
2025
Q2 		$2.26M Buy
598,630
+114,051
+24% +$449K ﹤0.01% 2626
2025
Q1 		$2.2M Sell
484,579
-12,716
-3% -$67.3K ﹤0.01% 2581
2024
Q4 		$3.52M Sell
497,295
-75,766
-13% -$603K ﹤0.01% 2502
2024
Q3 		$4.66M Sell
573,061
-33,710
-6% -$244K ﹤0.01% 2408
2024
Q2 		$3.88M Buy
606,771
+122,530
+25% +$787K ﹤0.01% 2459
2024
Q1 		$3.65M Sell
484,241
-37,121
-7% -$339K ﹤0.01% 2401
2023
Q4 		$4.83M Buy
521,362
+85,777
+20% +$701K ﹤0.01% 2328
2023
Q3 		$4.41M Buy
435,585
+17,380
+4% +$207K ﹤0.01% 2313
2023
Q2 		$5.23M Buy
418,205
+10,003
+2% +$119K ﹤0.01% 2225
2023
Q1 		$4.76M Buy
408,202
+28
+0% +$357 ﹤0.01% 2222
2022
Q4 		$4.34M Buy
408,174
+10,114
+3% +$97.6K ﹤0.01% 2293
2022
Q3 		$3.86M Buy
398,060
+11,454
+3% +$152K ﹤0.01% 2356
2022
Q2 		$5.6M Buy
386,606
+9,107
+2% +$155K ﹤0.01% 2141
2022
Q1 		$9.87M Buy
377,499
+8,499
+2% +$241K ﹤0.01% 1962
2021
Q4 		$14.6M Buy
369,000
+15,839
+4% +$722K ﹤0.01% 1794
2021
Q3 		$17.7M Buy
353,161
+98,463
+39% +$5.37M 0.01% 1679
2021
Q2 		$14.1M Buy
254,698
+27,499
+12% +$1.46M ﹤0.01% 1810
2021
Q1 		$10.6M Buy
227,199
+12,692
+6% +$615K ﹤0.01% 1929
2020
Q4 		$9.34M Buy
214,507
+12,024
+6% +$444K ﹤0.01% 1906
2020
Q3 		$7.41M Buy
202,483
+97,024
+92% +$3.3M ﹤0.01% 1865
2020
Q2 		$3.08M Buy
105,459
+34,240
+48% +$946K ﹤0.01% 2268
2020
Q1 		$1.86M Buy
71,219
+23,792
+50% +$727K ﹤0.01% 2299
2019
Q4 		$1.65M Buy
47,427
+1,201
+3% +$39.8K ﹤0.01% 2468
2019
Q3 		$1.46M Buy
+46,226
New +$1.82M ﹤0.01% 2476

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's HCAT Position: Q2 2026 in Review

Charles Schwab increased its Health Catalyst (HCAT) stake by 1.4% in Q2 2026, buying an estimated $12.5K and bringing the position to 615,504 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2945.

Charles Schwab first reported a position in HCAT in Q3 2019 and has held it in 28 quarters since. The position peaked at $17.7M in Q3 2021. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Charles Schwab held 615,504 shares of Health Catalyst worth $1.22M as of Q2 2026.
  • Charles Schwab bought 8,646 Health Catalyst shares in Q2 2026, an estimated $12.5K.
  • Health Catalyst made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2945 holding.
  • Charles Schwab first reported a position in Health Catalyst in Q3 2019 and has held it in 28 quarters since.
  • Charles Schwab's Health Catalyst position peaked at $17.7M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.